IL9 and mastocytosis: To directly prove this, we assessed susceptibility to inflammatory allergy of MC-deficient C57BL/6-KitW/W-v mice or Cftr−/− mice treated with the tyrosine kinase inhibitor imatinib known to inhibit IL-9-driven mastocytosis in the lung12.